Westfield Capital Management Company LP Decreased Alexion Pharmaceuticals (ALXN) Stake; BT GROUP PLC GBP (BTGOF) Shorts Increased By 513.55%

December 7, 2017 - By Nellie Frank

Westfield Capital Management Company Lp decreased Alexion Pharmaceuticals Inc (ALXN) stake by 7.78% reported in 2017Q2 SEC filing. Westfield Capital Management Company Lp sold 27,942 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 11.63%. The Westfield Capital Management Company Lp holds 331,270 shares with $40.31M value, down from 359,212 last quarter. Alexion Pharmaceuticals Inc now has $24.45B valuation. The stock increased 0.48% or $0.52 during the last trading session, reaching $109.42. About 1.94 million shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since December 7, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

BT GROUP PLC GBP (OTCMKTS:BTGOF) had an increase of 513.55% in short interest. BTGOF’s SI was 9.94 million shares in December as released by FINRA. Its up 513.55% from 1.62 million shares previously. With 7,600 avg volume, 1307 days are for BT GROUP PLC GBP (OTCMKTS:BTGOF)’s short sellers to cover BTGOF’s short positions. It closed at $3.45 lastly. It is down 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

BT Group plc provides communications services worldwide. The company has market cap of $32.93 billion. The Company’s Consumer segment sells telephones, baby monitors, and Wi-Fi extenders through high street retailers and the online BT Shop, as well as through Website BT.com; and offers home phone, copper and fiber broadband, TV, and mobile services in various packages. It has a 16.2 P/E ratio. The companyÂ’s EE segment offers 2G, 3G, and 4G mobile network services; and broadband, fixed-voice, and TV services, as well as postpaid and prepaid plans, and emergency services network.

Since June 14, 2017, it had 4 insider purchases, and 1 insider sale for $235.75 million activity. The insider HANTSON LUDWIG bought $1.17 million. COUGHLIN CHRISTOPHER J bought 2,000 shares worth $234,200. PARVEN ALVIN S sold $97,511 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, June 15. BAKER BROS. ADVISORS LP bought $77.53M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Wednesday, June 14.

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Alexion Pharmaceuticals Inc. had 86 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Neutral”. As per Thursday, July 27, the company rating was maintained by Jefferies. Leerink Swann maintained the shares of ALXN in report on Wednesday, September 13 with “Buy” rating. As per Friday, July 29, the company rating was maintained by Stifel Nicolaus. As per Friday, July 28, the company rating was maintained by BMO Capital Markets. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Friday, October 28 by Goldman Sachs. On Friday, July 31 the stock rating was maintained by UBS with “Buy”. On Tuesday, September 12 the stock rating was maintained by Stifel Nicolaus with “Buy”. Vetr upgraded the shares of ALXN in report on Wednesday, August 12 to “Buy” rating. The firm has “Buy” rating given on Tuesday, June 13 by BMO Capital Markets.

Westfield Capital Management Company Lp increased Univar Inc stake by 185,280 shares to 947,339 valued at $27.66 million in 2017Q2. It also upped Integra Lifesciences Hldgs C (NASDAQ:IART) stake by 111,091 shares and now owns 794,716 shares. Interxion Holding N.V (NYSE:INXN) was raised too.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.09 earnings per share, down 0.91% or $0.01 from last year’s $1.1 per share. ALXN’s profit will be $243.52M for 25.10 P/E if the $1.09 EPS becomes a reality. After $1.28 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.84% negative EPS growth.

Investors sentiment increased to 1.37 in 2017 Q2. Its up 0.23, from 1.14 in 2017Q1. It increased, as 55 investors sold ALXN shares while 146 reduced holdings. 72 funds opened positions while 203 raised stakes. 208.01 million shares or 0.31% less from 208.67 million shares in 2017Q1 were reported. Thrivent For Lutherans reported 0.43% stake. Art Advsr Llc stated it has 54,900 shares or 0.35% of all its holdings. Bokf Na holds 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 3,916 shares. Btg Pactual Asset Mngmt Ltd reported 3,868 shares. Profund Ltd Llc holds 0.55% or 100,538 shares in its portfolio. Eaton Vance Management has 0.27% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Marshall Wace Llp, United Kingdom-based fund reported 3,504 shares. Twin Cap Mgmt holds 0.19% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 26,010 shares. Enterprise Finance Svcs Corporation, Missouri-based fund reported 3 shares. Salem Investment Counselors has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Tokio Marine Asset Mngmt Company Ltd has 18,133 shares. Norinchukin Bankshares The owns 0.04% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 15,584 shares. Macquarie Gp holds 131,994 shares. Nj State Employees Deferred Compensation Plan stated it has 0.28% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). State Board Of Administration Of Florida Retirement holds 0.11% or 325,500 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Nellie Frank




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: